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Abstract The aim of the present study was to test if the
consumption of creatine incorporated in food bars modi-
fies creatine plasma kinetics, erythrocyte retention and
loss in urine and in feces when compared with its con-
sumption in the form of an aqueous solution (AS).
Seventeen healthy young men ingested 2 g creatine either
in the form of AS, or incorporated in a protein (PP)- or in
a beta-glucan (BG)-rich food bar. Kinetics of plasma
creatine was measured for 8-h duration and urinary
excretion for 24 h. Then, the subjects received the same
treatment thrice a day for 1 week at the end of which
creatine contents were determined in erythrocytes and in
feces (n = 4 for feces). The three crossover treatments
were interspaced by a 40 ± 1.2-day wash-out. Absorption
of creatine was slowed down by 8-fold in the presence of
BG (P \ 0.001) and by 4-fold with PP (P \ 0.001)
whereas the velocity rate constant of elimination and the
area under the curve were not modified. Urinary loss of
creatine in the first 24 h following ingestion was
15 ± 1.9% in AS and 14 ± 2.2% in PP conditions (NS),
whereas it was only 8 ± 1.2% with BG (P = 0.004).
Increase in creatine concentration in erythrocyte was
similar in whatever form the creatine was ingested. Cre-
atine seems to be totally absorbed since no creatine or
creatinine was detectable in feces. No side effects were
reported. In conclusion, ingestion of creatine combined
with BG facilitates its retention by slowing down its
absorption rate and reducing its urinary excretion.
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Introduction
Since the paper of Harris et al. (1992), creatine has become
one of the most popular dietary supplements in the world.
In 2000, the American College of Sports Medicine esti-
mated that 2,500 metric tons were consumed every year
(Terjung et al. 2000). Creatine improves sport performance
during repeated short-duration/high-intensity exercises
(Balsom et al. 1995) and amplifies the increase in lean
body mass and strength induced by resistance training
(Kreider et al. 1998). Creatine has also therapeutic benefits,
it accelerates skeletal muscle recovery after prolonged
immobilization (Hespel et al. 2001) and it slows down
muscle wasting in certain myopathies (Louis et al. 2003;
Tarnopolsky et al. 2004). Furthermore, more recent but
limited information indicates that creatine may improve
cognitive performance (McMorris et al. 2007).
Two strategies of supplementation exist. In most condi-
tions, 20 g creatine is ingested every day for 5 days,
increasing its muscle content by about 20% (Deldicque et al.
2005; Greenhaff et al. 1994). Thereafter, 3–5 g are con-
sumed daily to maintain its muscle uptake (Hultman et al.
1996). A second strategy omits the loading phase. In
this case, the rise in muscle creatine content is slower, but
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reaches the same level after about 15 days (Hultman et al.
1996). Other cell types, such as erythrocytes and neurons,
also store creatine during supplementation (Dechent et al.
1999; Preen et al. 2005). Nevertheless, the level of accu-
mulation is not necessarily correlated between tissues (Preen
et al. 2005).
A large fraction of the ingested creatine is excreted in
urine, from 33 to 77% of the original dose ranging from 8 to
21 g/day during 1–14 days (Poortmans and Francaux 2007).
This might potentially induce a kidney overload. A few renal
impairments have been reported (Koshy et al. 1999; Prit-
chard and Kalra 1998), although cohort studies have not
revealed any deleterious effects on renal functions (Francaux
and Poortmans 2006). Recently, increased excretion of
methylamine and formaldehyde, have been observed after
ingestion of large amounts of creatine (21 g/day) for
2 weeks (Poortmans et al. 2005). Although the level of these
two mutagenic agents remained within the normal range for a
healthy population, the development of strategies using low
doses of creatine is wanted for reducing the potential risks
induced by supplementation with larger amounts. These
strategies should lead to a better retention of creatine by the
body and thus, to a lower urinary excretion.
One of the most obvious ways to reach this goal is to
slow down the velocity of intestinal absorption of creatine
by adding fibers to the bolus. Beta-glucans are structural
polysaccharides present as dietary fibers in barley and oat
grains. Their water-soluble properties as well as their
chemical structure help to increase the viscosity of foods.
Beta-glucans are known to reduce the rate of carbohydrate
and lipid absorption (Lifschitz et al. 2002; Wursch and
Pi-Sunyer 1997). The first hypothesis of the present study
is that beta-glucans consumed with creatine could slow
down the rate of absorption of the latter and consequently
favour its retention by the body.
Athletes often combine creatine with protein supple-
ments expecting an enhancement of protein synthesis
through a higher amino acid availability. The presence of
food, other than fibers, within the gastrointestinal tract
markedly changes the velocity of absorption of drugs and
dietary substances and potentially alters their bioavail-
ability (Welling 1977). Therefore, our second hypothesis is
that the rate of creatine absorption would also be slowed
down when combined with the ingestion of solid foods,
amongst others food eaten by athletes.
Little is known on the bioavailability of creatine
ingested as a dietary supplement. Otto Folin (1906) was
unable to find any trace of creatine in the feces and Cha-
nutin (1926) suggested that creatine is completely absorbed
by the intestinal tract.
In the present study, we tested if the consumption of
creatine incorporated in food bars rich in beta-glucans or in
proteins, could modify creatine plasma kinetics,
erythrocyte retention and loss in urine and in feces when
compared to its supplementation in aqueous solution (AS).
Materials and methods
Subjects
Seventeen healthy males (21 ± 0.3 years, 179 ± 1.0 cm,
71 ± 2.9 kg, mean ± SEM) were recruited. They were
physically active, although none of them was a high-level
athlete. They were instructed to keep their diet and their
physical activity unchanged during the experiment. Food
intake was recorded for 7 days, prior to the beginning of
the experiment, by means of a standardized questionnaire
and computed using the Nutrilog software (Marans,
France). Daily energy intake was 2447 ± 111.7 kcal divi-
ded into 48 ± 1.1% carbohydrates, 34 ± 1.1% lipids,
3 ± 0.8% alcohol and 15 ± 1.1% proteins which corre-
spond to 1.3 ± 0.10 g of proteins per kg body mass. The
subjects did not consume any food supplement for at least
2 months and they did not take any drug on a regular basis.
They were given an oral and written account of the study
before signing an informed consent document. This study
was approved by the Ethic Committee of the Universite´
catholique de Louvain and all the procedures used were in
accordance with the Declaration of Helsinki.
Protocol
The subjects received randomly three treatments, which
were interspaced by a wash-out period of 40 ± 1.2 days,
with a range between 29 and 57 days. This duration was
chosen because a period of 28 d without creatine was
reported to be sufficient to restore intramuscular creatine
level to basal concentrations (Febbraio et al. 1995). One
treatment consisted in 2 g creatine powder (2.3 g creatine
monohydrate, food grade, CreapureTM), consumed in
150 ml of AS. The two others were food bars with com-
mercial recipes manufactured for the study by the Nestle´
Product Technology Center PTC-Orbe, Switzerland: one
was a protein-rich bar (PP) and the other one was a beta-
glucan-rich bar (BG). The protocol is summarized in Fig. 1.
The BG-bar contained 16.7 g carbohydrates, 4.1 g pro-
teins, 2.3 g lipids and 3.2 g fibers (*1.5 g beta-glucans) and
a total energy content of 104 kcal. The PP-bar contained
19.0 g carbohydrates, 14.3 g proteins, 1.3 g lipids and 0.1 g
fibers and a total energy content of 144 kcal. Both bars also
contained 2 g of creatine, as checked by subsequent analysis,
incorporated as monohydrate at manufacture.
The day before the experiment, the subjects received
standardized meals and were asked to collect their 24 h urine
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production. Following an overnight fast, they arrived at 7.00
a.m. in the laboratory and were weighed. They filled in a
binary (yes/no) questionnaire assessing the occurrence of
adverse symptoms over the past 7 days (stomachache,
diarrhea, constipation, nausea, headache, dizzy spell,
blackout, pounding, insomnia, tendonitis, cramps, muscle
soreness, fatigue, loss of appetite, hunger and other com-
plaints). A catheter was introduced into an antecubital vein
and a first blood sample was drawn to determine the basal
level of creatine and creatinine in plasma and erythrocytes.
Then, the subjects ingested one of the three creatine products
(AS, BG or PP) and 16 blood samples were further taken up
during the next 8 h to determine the plasma kinetics of cre-
atine and creatinine. A standardized breakfast, snack, lunch
and a last snack were given, respectively, 2, 4, 5 and 7 h after
creatine ingestion. Similarly, urines were collected 2, 4, 8
and 24 h after creatine ingestion. The subjects were
instructed to consume the test product thrice a day, in the
morning, at noon and in the evening, for the next 7 days. On
day 8, the subjects returned to the laboratory after an over-
night fast. They were weighed again and a blood sample was
drawn for plasma and erythrocyte creatine and creatinine
determination. The health status questionnaire was filled in
again. Four of the subjects collected their 24-h feces six times
on the day before and the last day of each supplementation
period.
Procedures
Venous blood was collected on heparin as an anticoagulent.
The tubes were placed immediately on ice and centrifu-
gated at 3,000g for 6 min at 4C. Plasma (900 ll) was
deproteinized with sulfosalicylic acid 5% (300 ll) and
centrifugated again at 3,000g for 6 min. NaOH 0.1 M
(90 ll) was added to supernatant (300 ll) to obtain a pH
value of about 7.8. Samples were stored at –20C.
After the first centrifugation, erythrocytes were washed
twice with a similar volume of physiological water (0.9%
NaCl, centrifugation 1,000g, 5 min, 4C). After three fro-
zen and defrozen procedures, erythrocytes (300 ll) were
deproteinized with sulfosalicylic acid 5% (600 ll) and then
centrifugated at 3,000g during 6 min. Supernatant was
collected and centrifugated again. The clear supernatant
was neutralized with NaOH 0.1 M.
Urines were collected in a plastic bottle and the volume
was measured. An aliquot (10 ml) was stored at –20C.
Creatine and creatinine content in plasma, erythrocytes
and urine were analyzed by spectrophotometry by enzy-
matic technique (Siedel et al. 1984), omitting creatininase
for creatine determination. Creatine and creatinine content
in test bars were determined by HPLC following homo-
geneization and solvent extraction according to a modified
method of Dash and Sawhney (2002).
The 24-h collection of feces was placed in a plastic box
and weighed. An aliquot was stored at –80C. Due to the
large bacterial content, the feces were prepared as soon as
possible, avoiding the acidic deprotenization step that might
induce a degradation of creatine to creatinine (Ganguly et al.
2003).
Both creatine and creatinine content in feces was analyzed
by HPLC at 205 nm. After dilution of a feces aliquot in
0.045 M ammonium sulfate containing an internal standard
(4-[2-aminoethyl]-benzene sulfonamide), the sample was
filtered on a 10 kDa. The following conditions were used to
identify creatine: 2 Beckman RP-C18 Ultrasphere ODS
columns 5 lm 25 cm · 4.6 mm; elution: A/B (70/30) with
0.05% anhydrous trifluoroacetic acid (TFA) at 1.0 ml/min;
A: 0.1% H3PO4 in deionized H2O; B: 1.4 mg sodium
dodecylsulfate/ml acetonitril. Spectral profiling (Diod Array
Detector series 200 HP) demonstrated that the small peak
corresponding to creatine in the samples was heterogeneous.
The values reported for creatine in the results section cor-
respond to highest possible estimates including a probable
overestimation. Creatinine was detected according to
another modified method (Dash and Sawhney 2002) using
the same columns as for creatine but a different elution:
ammonium sulfate 5.95 g/l deionized H2O at 1.0 ml/min.
Due to the nature of the elution solvent and the small size of
the creatinine peak, its spectral profile could not be obtained.
As for creatine, the reported values correspond to highest
possible estimates.
Pharmacokinetics
Using a Marquardt algorithm, all kinetics were fitted with
the following equation:
C ¼ ðFD=V  ðka=ðka  kelÞÞ  ðexpðkel  ðt  tlagÞÞ
 expðka  ðt  tlagÞÞÞÞ
ð1Þ
where C is the plasma creatine concentration minus the basal
concentration (lM; if C £ 0, then data were removed); F is
the bioavailability; D is the dose (2 g or 15 300 lmol); V is
Fig. 1 Experimental protocol
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the volume of distribution; ka is the velocity constant of
absorption (first order, h–1); kel is the velocity constant of
elimination (first order, h–1); t is the time (h); tlag is the lag-
time (h); No weight was applied to data (weight = 1) and the
initial parameters values were estimated using a Simplex
algorithm. This equation corresponds to a one-open com-
partmental model in which ka, kel and tlag are the primary
parameters. Knowing their value, new kinetic parameters of
plasma creatine were calculated. AUC0,? is the area under
the curve integrated from zero to infinity. Since the bio-
availability (F) may not be measured, only the apparent
volume of distribution and the apparent clearance can be
estimated. Vd is the apparent volume of distribution, Vd = V/
F (l) and Cl is the apparent clearance, Cl = kel Vd (l h
–1)
Statistics
Results are presented as the means ± standard errors of the
means (SEM). Differences between mean values of vari-
ables measured with the three forms of creatine ingestion
(AS/BG/PP) were assessed by a mixed model representing
the order of the treatments (first, second or third treatment)
and when applicable, the time of measurement (pre- and
post-treatment). When the variable tested was not affected
by the order, either a one-way (single dose) or a two-way
ANOVA (multiple doses) for repeated measures was used.
When a one-way ANOVA was used, the Dunnett test was
used as post hoc test to compare BG and PP with AS as the
reference treatment. In the case of a two-way ANOVA, the
Bonferroni test was applied as post hoc test to compare pre-
and post-treatment conditions. Statistical significance of
changes observed in frequencies of discrete variables was
inferred by means of a Fisher-test. The significant threshold
was set at P \ 0.05.
Results
Kinetics after a single dose
Urines
In basal conditions, 24 h urinary excretion of creatine was
2 ± 1.9 mg. When a single dose of 2 g creatine was
consumed in the form of AS and PP, 15 ± 1.9% and
14 ± 2.2% of the dose, respectively, was found in urine
collected during the first 24 h after ingestion (Fig. 2). Less
creatine was excreted after the BG treatment (8 ± 1.2%,
P = 0.004), as compared to AS and PP forms. Most of the
excreted creatine appeared in urine during the first 2 h
following intake of AS (Table 1). After 4 h, creatine
excretion values became similar to basal conditions.
Creatinine urinary excretion was slightly less than 1 g/
24 h and not affected by ingestion of 2 g creatine whatever
the form of ingestion.
Neither creatine, nor creatinine excretions were affected
by the order of the treatment.
Plasma concentrations
The mean basal plasma creatine concentration was
10 ± 1.0 lM (Fig. 3). After ingestion of 2 g creatine in the
form of AS, plasma concentration increased sharply to reach
a peak (299 ± 19.5 lM) in less than 1 h (Table 2). When the
same amount of creatine was consumed as a bar, plasma
concentration increase was slower; maximal plasma con-
centration was lower and delayed (Table 2). ANOVA design
for repeated measures applied to the kinetic data showed a
significant interaction between time and treatments
Fig. 2 Percentage of initial dose of creatine (2 g) excreted in urines
in 24 h. Creatine was ingested as an aqueous solution (AS), or
incorporated in a beta-glucan- (BG) or protein- (PP) rich food bar. P
values above histograms depict statistical significances of differences
with AS treatment
Table 1 Creatine urinary excretion
0–2 h 2–4 h 4–8 h 8–24 h
AS 0.193 ± 0.0204 0.107 ± 0.0217 0.002 ± 0.0010 0.001 ± 0.0001
BG 0.035 ± 0.0087*** 0.108 ± 0.0195 0.010 ± 0.0051 0.001 ± 0.0003
PP 0.152 ± 0.0250 0.117 ± 0.0223 0.004 ± 0.0022 0.002 ± 0.0009
Urinary creatine excretion (g) during the first 2 h, between the 2nd and the 4th hour, between the 4th and the 8th hour and between the 8th and the
24th hour after ingestion of 2 g creatine under the form of an aqueous solution (AS), or incorporated in a beta-glucan- (BG) or protein- (PP) rich
food bar. Results are expressed as the means ± SEM (n = 17). ***P \ 0.001 versus AS treatment
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(P \ 0.001) indicating different time-courses according to
the ingested forms (AS/BG/PP). Post hoc analyses showed
that the difference emerged during the absorption phase
before the peak concentrations were reached (Fig. 3). The
peak creatine concentration was lower with BG
(174 ± 14.0 lM) than with PP (237 ± 22.3 lM, P = 0.019)
and the peak concentration appeared later (2.40 ± 0.177 h
with BG vs. 1.31 ± 0.150 h with PP, P \ 0.001).
The one-open compartment model described by Eq. 1
yielded the best fitting of the plasma creatine time-course
(Fig. 4). Other tested models did not allow the algorithm
converging or gave larger residuals. Using Eq. 1, the median
value of residuals was 1.06 lM in AS condition. The first and
the third quartiles were –8.90 and 9.97 lM, respectively.
The distributions of residuals were not different in BG
and PP conditions where the medians were –0.49 lM (25%,
–10.04 lM to 75%, 8.67 lM) and 0.04 lM (25%,
–10.13 lM to 75%, 7.98 lM), respectively. The
relationships between observed and calculated plasma cre-
atine concentrations were linear and explained a high
fraction of variances: 96% in AS; 88% in BG; and 95% in PP
condition.
The lag-time (tlag), the velocity constant of elimination
(kel) and the velocity constant of absorption (ka) are the
three calculated parameters of Eq. 1. The mixed model
analysis did not reveal any effect of the order by which the
treatment were given to the subjects, as far as tlag, kel and ka
mean values are concerned.
The lag-time (tlag) corresponds to the time necessary to
observe a change in plasma creatine concentration after the
bolus ingestion. When creatine was ingested under AS and
PP forms, the tlag appeared 0.38 ± 0.033 h and 0.43 ±
0.060 h, respectively (P = NS), but tlag doubled when
creatine was ingested as a BG bar (0.78 ± 0.114 h,
P \ 0.001, Table 2)
The velocity constant of absorption (ka) was faster when
creatine was ingested under the form of AS in comparison
with the bars (P \ 0.001, Table 2). The time of absorption
(Tabs) is inversely related to ka. Tabs was 0.55 ± 0.150 h in
AS condition, whereas it reached 2.18 ± 0.385 h in PP (P\
0.001) and 4.67 ± 0.267 h in BG condition (P \ 0.001).
The mean half-life of elimination was 1.09 ± 0.060 h.
Neither the velocity constant of elimination, nor the apparent
clearance was affected by the form of creatine ingested
(Table 2). The apparent volume of distribution was about
75% of body mass and was not influenced by the form of
creatine ingested (Table 2). The areas under the curve cal-
culated by integration of Eq. 1 from 0 to infinity (AUC0,?)
were identical for all creatine forms (mean value:
539 ± 30.4 lM h, Table 2).
Table 2 also presents the results of the subgroup of
subjects (n = 7) receiving AS as first treatment.
Mean value of plasma creatinine concentrations in basal
condition was 53.5 ± 1.50 lM. It changed by only a few
lM during the 8 h following ingestion of creatine inde-
pendently of the treatment.
Fig. 3 Kinetics of plasma creatine after an ingestion of 2 g creatine.
The results are expressed as the means ± SEM (n = 17). *P \ 0.05,
#P \ 0.01, §P \ 0.001 versus AS treatment same time
Table 2 Plasma kinetic data
First trial AS (n = 7) AS (n = 17) BG (n = 17) PP (n = 17)
Peak concentration of plasma creatine (observed, lM) 312 ± 41.5 299 ± 19.5 174 ± 14.0*** 237 ± 22.3*
Time to peak concentration (observed, h) 0.86 ± 0.092 0.81 ± 0.050 2.40 ± 0.177*** 1.31 ± 0.146*
Lag-time (h) 0.42 ± 0.060 0.38 ± 0.033 0.78 ± 0.114*** 0.43 ± 0.060
Velocity constant of absorption (h–1) 25.44 ± 8.780 23.63 ± 6.655 0.78 ± 0.045*** 4.58 ± 7.050**
Time of absorption (h) 0.34 ± 0.102 0.55 ± 0.150 4.67 ± 0.267*** 2.18 ± 0.385***
Velocity constant of elimination (h–1) 0.79 ± 0.111 0.68 ± 0.058 0.71 ± 0.056 0.74 ± 0.056
Area under the curve (0??, lM h) 511 ± 86.5 587 ± 56.2 501 ± 44.9 528 ± 57.0
Apparent volume of distribution (l) 49.4 ± 8.51 47.1 ± 4.16 55.5 ± 8.88 60.6 ± 14.68
Apparent clearance (l h–1) 42.6 ± 14.01 33.7 ± 6.22 35.4 ± 3.87 38.9 ± 6.70
Plasma kinetic data after an ingestion of 2 g creatine. AS aqueous solution, BG beta-glucan-rich bar, PP protein-rich bar. First trial AS reports
results of subjects receiving AS as first treatment. The results are expressed as the means ± SEM. *P \ 0.05, ***P \ 0.001 versus AS treatment
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Ingestion of multiple doses
Body mass
Body mass was affected by the order of the treatments
demonstrating a progressive increase in body mass across
the trials (P \ 0.001). The mean body mass values were
68.2 ± 1.45 kg before the first trial, 68.8 ± 1.49 kg before
the second trial and 69.7 ± 1.54 kg before the third one.
Considering the factor ‘‘order’’, the mixed model was
unable to demonstrate any further changes in body mass in
whatever the form the creatine was ingested (Table 3).
Considering that the progressive increase in body mass
observed during the whole period of experimentation might
be due to the energy contained in the bars, the order factor
was replaced in the mixed model by a carry-over factor, i.e.
a factor representing the previous treatment (AS/BG/PP).
Indeed, AS treatment only provided a negligible amount of
energy compared to BG and PP bars and therefore, one
could hypothesize that PP and BG treatments induced
changes in body mass whereas AS does not. The results of
the statistical analysis did not show a significant carry-over
effect suggesting that the form of the previous treatment
had no influence on body mass during the subsequent trial.
Therefore, the increase in body mass following the first
treatment was most probably due to the ingestion of crea-
tine. As observed for plasma creatinine (see below), the
increase in body mass suggests that the period between
treatments was too short to enable baseline creatine levels
to be attained. Nevertheless, due to the design of the study
this would not invalidate the main conclusions.
Plasma concentrations
After 1 week of creatine supplementation, plasma creatine
and creatinine concentrations were measured again in a
fasted state. Plasma creatine concentration, the value of
which was not influenced by the order of the treatments,
was 11 ± 2.5-fold higher after supplementation (Fig. 5a).
The increase after PP creatine form was lower
(+30 ± 5.2 lM) than after AS and BG supplementation
(+86 ± 33.5 lM and + 85 ± 14.3 lM, respectively), with a
significant interaction between treatments (AS/BG/PP) and
conditions (pre-/post-supplementation). There was a sig-
nificant order effect for creatinine plasma concentration
(P \ 0.001). The basal mean values were 49.0 ± 2.22 lM,
54.7 ± 3.30 lM and 56.8 ± 1.83 kg for the first, second
Fig. 4 Kinetics of plasma creatine after an ingestion of 2 g creatine.
The fitted curve is given by Eq. 1 (see ‘‘Materials and methods’’). AS
aqueous solution, BG beta-glucan-rich bar, PP protein-rich bar. The
results are expressed as the means ± SEM (n = 17)
Table 3 Body mass
Before After
AS 68.9 ± 1.53 69.2 ± 1.56
BG 69.1 ± 1.53 69.6 ± 1.54
PP 69.0 ± 1.43 69.8 ± 1.50
Body mass (kg) before and after 1 week creatine supplementation
(3 · 2 g per day). Creatine was administered under the form of an
aqueous solution (AS), or incorporated in a beta-glucan- (BG) or
protein- (PP) rich food bar. Results are expressed as the means ±
SEM (n = 17)
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and third trial, respectively. Despite the progressive
increase in the basal concentration over the time of the
experimentation, 1-week creatine supplementation slightly
increased plasma creatinine concentrations by all treat-
ments (P \ 0.05), independently of the form of the
ingested creatine form (Fig. 5b).
Erythrocyte concentrations
Erythrocyte creatine concentration showed large inter-
individual differences as illustrated by a coefficient of
variation of basal values of 59%, but was not influenced by
the order of treatments. It was increased by 88 ± 22% after
creatine supplementation independently of the form of
ingested creatine (Fig. 6). There was no significant inter-
action between treatment (AS/BG/PP) and condition (pre-/
post-) indicating that the form of creatine ingested had no
further influence on the erythrocyte creatine level.
Basal erythrocyte creatinine concentration was about
25 lM and remained stable throughout the entire
experiment.
Feces
Whatever the conditions, basal or supplemented, creatine
and creatinine could not be quantified in human feces. The
methods used were sufficiently sensitive to indicate that the
maximal estimated value was *15 ± 1.2 lg/g fresh feces
for creatinine and *50 ± 5.7 lg/g fresh feces for creatine.
Side effects
During the initial visit and after each period of creatine
supplementation, all subjects filled in a questionnaire list-
ing potential side effects. No difference was observed in
the frequency of declared health troubles except for muscle
cramps, which were less frequently reported after creatine
supplementation (P \ 0.05).
Discussion
Although creatine is widely used as a dietary supplement,
only few studies aimed to describe its pharmacokinetics
(Fitch and Sinton 1964; Green et al. 1996; Harris et al.
1992; Schedel et al. 1999; Vanakoski et al. 1998). After
ingestion of a single low dose, the time-course of plasma
concentration is generally accepted to follow a one-open
compartment model with first-order absorption and elimi-
nation constants (Persky et al. 2003). The results of the
Fig. 5 Plasma creatine a and creatinine b concentrations measured
before (black) and after 1 week (grey) creatine supplementation
(3 · 2 g per day). P values above histograms depict statistical
significances of differences between pre- and post- creatine supple-
mentation. AS aqueous solution, BG beta-glucan-rich bar, PP protein-
rich bar. The results are expressed as the means ± SEM (n = 17)
Fig. 6 Erythrocyte creatine concentration measured before (black)
and after 1 week (grey) creatine supplementation (3 · 2 g per day). P
values above histograms depict statistical significances of differences
between pre- and post- creatine supplementation. AS aqueous
solution, BG beta-glucan-rich bar, PP protein-rich bar. The results
are expressed as the means ± SEM (n = 17)
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present study support this statement. Models with a zero-
order constant of absorption and with a bi-exponential
elimination phase were tested and yielded unsatisfying
fittings.
Once ingested, creatine has potentially various fates.
Due to the low pH in the stomach, it could be transformed
in creatinine. However, the rate of conversion is rather
slow (Cannan and Shore 1928). The half-lives of degra-
dation are 55, 7.5 and 40.5 days at pH values 1.4, 3.7 and
6.8, respectively (Chanutin, 1926). Thus, considering a pH
of stomach near to 2 and a dose of 2 g, only 1% of this
amount would be converted to creatinine within the first
hour after ingestion. This rate of creatine degradation is in
the same range in the intestinal tract (pH = 6–7). As cre-
atine remains a longer period of time in the intestine than in
the stomach, it is likely to be degraded in a larger pro-
portion at this level. However, the stable plasma creatinine
concentration following ingestion of creatine, in addition to
its undetectable amount in feces, corroborate the hypoth-
esis that the conversion of creatine to creatinine remains
negligible in the gastrointestinal tract.
Under conditions that exist in stomach, creatine can
theoretically be converted to N-nitrososarcosine (Archer
et al. 1971). Creatine can also be degraded to sarcosine by
microbial reactions (Wyss and Kaddurah-Daouk 2000) and
therefore, give rise to intestinal methylamine and formal-
dehyde. Experimental protocols carried out in humans
ingesting large amounts of creatine did not reveal any
increase in urinary nitrosarcosine (Derave et al. 2006), but
reported a higher excretion of methylamine and formal-
dehyde, although the latter remained within a normal range
(Poortmans et al. 2005). To the best of our knowledge, no
publications have yet reported the presence of N-nitroso-
sarcosine, methylamine or formaldehyde in feces. Even if
these substances might be potentially toxic, such transfor-
mations are quantitatively negligible and the bulk of
creatine ingested remains available for absorption.
In the pharmacokinetic model, the lag-time represents the
time between creatine ingestion and the onset of the rise in
plasma concentration. The lag-time was 0.38 ± 0.033 and
0.43 ± 0.060 h after ingestion of creatine in fasted state
under AS and PP forms, respectively, but was doubled with
BG-rich bar (0.78 ± 0.114 h, P \ 0.001). This indicates that
the presence of BG in the meal slows down the velocity of
transit probably by increasing the viscosity of the bolus
(Wursch and Pi-Sunyer 1997).
Once in the small intestine, creatine is taken up by an
active, saturable end electrogenic Na+:Cl– cotransporter
located at the brush-border membrane (Peral et al. 2002).
This protein is a member of the superfamily of Na+:Cl–
dependent transporters responsible for the uptake of certain
amino acids (e.g., glycine and proline) and other molecules
like dopamine, GABA, serotonin, taurine and betaine
(Guimbal and Kilimann 1994; Nelson and Lill 1994).
Experiments using these substances revealed a high spec-
ificity of the creatine transporter (Km = 29 lM; Peral et al.
2002). The fact that the kinetics of plasma creatine corre-
sponds to a first-order model suggests that the transporter is
not saturated by a single dose of 2 g creatine.
The velocity constant of creatine absorption was slower
when incorporated in a PP-rich bar (4.58 ± 7.050 h–1) as
compared to AS form (23.63 ± 6.655 h–1, P \ 0.01). Due
to the high specificity of the creatine transporter in the
small intestine (Peral et al. 2002), the slower rate of
absorption cannot be explained by a competition with
amino acids. The presence of a bolus in the gastrointestinal
tract diminishes the rate of absorption of drugs (Welling
1977). It seems that the same phenomenon could occur
with creatine. Moreover, BG are viscous polysaccharides
that result in a slower rate of carbohydrate and lipid
absorption when included in a meal (Lifschitz et al. 2002).
This property of BG makes the rate of absorption even
slower and cannot be explained by the presence of the
bolus alone (Bonferroni-test PP vs. BG, P \ 0.05).
Therefore, the results of the present study also reveal that
BG form reduces the absorption rate of substances other
than carbohydrates and lipids.
Bioavailability (F) did not seem to be affected by the
form of ingested creatine since the AUC integrated from
zero to infinity were not different. This observation con-
tradicts the findings of an altered bioavailability when
creatine is ingested as a lozenge or in suspension (Harris
et al. 2002). The results of the latter study were discussed
by Persky et al (2003) who pointed out that AUC was
integrated from 0 to 6 h, whereas integration to infinity is
necessary to assess the pertinence of bioequivalence.
As mentioned, the transformation in gastrointestinal
tract of creatine into other compounds is quantitatively low
compared to the transit duration. We did not find detectable
amount of creatine in the feces after 1 week creatine sup-
plementation (3 · 2 g/day) indicating that creatine is
completely absorbed. There is no reason to believe that
creatine would be taken up first by the liver and therefore,
most of the creatine ingested would appear in arterial
blood. However, creatine is obviously taken up by different
cells (e.g., muscles, erythrocytes, etc.) before reaching
venous blood. Thus, it is likely that the arterial bioavail-
ability nearly reaches 100%, whereas it will be lesser at the
venous level. Since Vd = V/F (see above), it sounds rea-
sonable to find an apparent larger volume of distribution
(Vd) as compared to the extracellular space (Table 2).
Previous studies reported that a large proportion of
creatine ingested (40–72%) is excreted in urine (Poortmans
and Francaux 2007). Figure 2 shows that this proportion
can be reduced to about 15% by giving smaller amount of
creatine (namely 2 g).
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The half-life of elimination is about 1 h whatever form
the creatine was ingested. Considering the low rate of
metabolic degradation of creatine (see above), the amount
appearing in blood is either eliminated in urine or taken up
by the tissues. Since the AUC is not different between
treatments, it may be assumed that the amount of creatine
appearing in blood remains similar. Therefore, the lower
urinary excretion in BG than in AS implies a larger uptake
by tissues. This difference appears within the first 2 h after
creatine ingestion (Table 1) and is likely due to a slower
absorption rate with BG, which results in a lower and
delayed plasma peak concentration (Table 2). Although,
PP had similar effects, it does not reduce the absorption
rate sufficiently enough to modify the urinary excretion of
creatine.
In this study, the pharmacokinetics after multiple doses
has not been investigated. Evidence suggests that the
absorption of creatine is saturable and therefore that its
kinetics is nonlinear in such conditions with respect to dose
size and frequency (for review, see Persky et al. 2003). On
the other hand, tissues such as skeletal muscle have a
limited capacity to accumulate creatine (Harris et al. 1992)
and the saturation of these stores could potentially affect
the value of the velocity constant of elimination. Therefore,
the model of Eq. 1 and the parameters values presented in
Table 2 are certainly not suitable for a regimen of multiple
doses. After 1-week supplementation (6 g/day) and one
night fast, plasma creatine concentration remained signifi-
cantly elevated in AS and BG conditions, but the statistical
threshold was not reached with PP due to the large inter-
individual variability. Lack of compliance could be evoked
to explain this result. But since the erythrocyte content
increased similarly in the three conditions (Fig. 6), this
hypothesis is unlikely. Actually, we have no arguments
which can explain this observation.
Several publications investigated the creatinine excre-
tion rate after ingestion of repeated doses of creatine. Some
showed an increase in creatinine excretion (Crim et al.
1975; Hultman et al. 1996), while others did not observe
any changes after short-term (Maganaris and Maughan
1998), medium-term (Vandenberghe et al. 1997) or long-
term (Poortmans and Francaux 1999) oral creatine sup-
plementation. In the present study, the daily ingestion of
three doses of 2 g creatine, slightly but significantly
increased plasma creatinine concentration after 1 week
independently of the form of the treatment (Fig. 5b).
Although, renal clearance of creatinine was not measured,
it is unlikely that this change reveals a drop in glomerular
filtration rate. In most kidney diseases, plasma creatinine
levels are much higher than the normal upper range limit of
1.5 mg% (*130 lM). The present values are largely
below this level (Fig. 5b). Moreover, our previous inves-
tigations never observed any changes in the glomerular
filtration rate, expressed by the creatinine clearance
(Poortmans and Francaux 1999, 2002). Creatine stored in
tissues is degraded by a non-enzymatic reaction into cre-
atinine. Therefore, a higher creatine concentration in
tissues induces a higher creatinine production according to
the mass action law and its diffusion to the plasma.
Although the washout period was 40 ± 1.2 days, the
first and the second supplementation periods increased
slightly but significantly the plasma creatinine concentra-
tions measured during the subsequent trial (P \ 0.001).
This suggests that certain tissues (e.g., the muscle) still
release a higher than basal amounts of creatinine at the
time the next trial began. Given the nature of the conver-
sion of creatine to creatinine (non enzymatic, first order,
1.67% per day), the whole body creatine content did not
regain the basal level prior to the second and the third
treatments. Although there is no statistical differences in
the kel values measured during the first, second and third
trial, the more reliable measurements of elimination are
those gained following the first treatment where kel =
0.78 ± 0.063 h–1 (Table 2).
Basal values of erythrocyte creatine concentrations
reported in the present study are in the same range as those
reported by other authors (Buysse et al. 1990; Jiao et al.
1998; Preen et al. 2005). After supplementation, it
increased independently of the form of the treatment to
reach approximately 500 lM (+88%, Fig. 6) confirming
that creatine is taken up by the erythrocytes. Accretion
seems dose-dependent since supplementation of 20 g a day
for 5 days leads to a 130 ± 30% increase of creatine in
erythrocytes (Preen et al. 2005).
A side effect of oral creatine supplementation regularly
mentioned by consumers is the increase in body mass
(Francaux and Poortmans 2006). In the present experiment,
changes in body mass due to creatine were not specifically
assessed. Nevertheless, it is possible that this often reported
effect was blunted by the progressive increase in body
mass observed during the experimentation (3–4 months by
subjects). This increase might be due to (1) a washout
period which did not allow a complete recovery of body
mass after creatine supplementation, (2) the energy con-
tained in the bars and (3) an undetermined cause of body
mass increase. The statistical analysis including a carry-
over factor ruled out the second hypothesis. Since the
protocol did not include a placebo group, we were not able
to distinguish between the first and the third hypothesis.
No deleterious effect of creatine consumption was
reported by the subjects whatever form the creatine was
ingested. This confirms other studies summarized in
Francaux and Poortmans (2006). The higher occurrence of
muscle cramps in basal conditions is probably due to a bias
related to the level of physical activity during the week
preceding the first visit.
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Ingestion of a single-dose of creatine (2 g) combined
with BG facilitates its retention by slowing down the
absorption rate and its urinary excretion. The present study
demonstrates clearly that gastrointestinal absorption is
complete, without any fecal waste, during a multiple-dose
supplementation (3 · 2 g/day for 7 days). During such
protocol, the erythrocyte creatine content increases mark-
edly, though there was no evidence that the form of the
ingested creatine made a difference. Future studies might
look at muscle creatine.
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